4SC

Contact
4sc.de
+49897007630

4SC AG

Am Klopferspitz 19 A
82152 Martinsried
Germany
+49897007630
4sc.de
Contact
Profile News
Contact

About 4SC

4SC AG is a drug discovery and development company that derives its competitive advantage from addressing critical medical needs through its unique cheminformatics based technological plattform.

Read more about 4SC
Facts about 4SC
  • Focus : Service
  • Employees: 51-200
  • Industry : Pharma

News about 4SC

4SC

17-Aug-2015 | research and development

4SC strengthens patent protection for its epigenetic cancer drug in China

4SC AG announced that it has further strengthened the patent protection for its epigenetic anti-cancer compound 4SC-202 - a selective inhibitor of LSD1 and ...

Read news
4SC

27-Feb-2013 | business & finance

4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases

4SC AG  announced that its fully-owned research subsidiary 4SC Discovery GmbH has entered into an exclusive research and license agreement with LEO Pharma ...

Read news
4SC

20-Apr-2012 | business & finance

4SC Discovery and CRELUX enter into strategic alliance

The biotech company 4SC AG announced that its drug discovery affiliate 4SC Discovery GmbH and CRELUX GmbH have entered into a strategic partnership for ...

Read news
4SC

20-Apr-2011 | research and development

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

4SC AG and Yakult Honsha Co.; Ltd. announced the grant of an exclusive license by 4SC to Yakult Honsha for the development and commercialization of ...

Read news
4SC

19-Jul-2010 | business & finance

4SC Awarded First Place and International Platinum Award for its 2009 Annual Report in the Biotech Category

4SC AG won first place and the platinum award, the highest level award, from the League of American Communications Professionals (LACP) for its annual ...

Read news
4SC

16-Feb-2010 | research and development

4SC Announces Treatment of First Patient in a Phase I Study of 4SC-205

Oral Eg5 kinesin spindle protein inhibitor to be evaluated in solid tumour and malignant lymphoma patients

Read news
4SC

23-Dec-2009 | research and development

4SC Announces Clinical Advancements in its Oncology Pipeline

4SC AG announced progress in the initiation of three new clinical trials for its oncology franchise: - Initiation of a Phase II trial with the oral, pan ...

Read news
Show more news about 4SC

Here you will find 4SC AG